IMMIX BIOPHARMA, INC. Capital Expenditures
IMMIX BIOPHARMA, INC. (IMMX) reported Capital Expenditures of $53.53 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $21.04K, a 83.51% decline year-over-year.
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $32.49K, a 52.02% decline year-over-year.
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $165.13K, a 67.44% decline year-over-year.
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $372.46K, a 37.16% increase year-over-year.
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $732.92K, a 37.77% decline from fiscal 2024.
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $1.18M, a 2160.90% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $52.09K.
- IMMIX BIOPHARMA, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $802.00.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $53.53K 10-Q · filed 2026-08-07 | $218.66K derived: sum of 3 quarters · filed 2026-08-07 | $591.11K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $32.49K 10-Q · filed 2026-05-07 | $197.61K derived: sum of 2 quarters · filed 2026-05-07 | $570.07K derived: sum of 3 quarters · filed 2026-05-07 | $697.70K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $165.13K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $537.58K derived: sum of 2 quarters · filed 2026-03-27 | $665.21K derived: sum of 3 quarters · filed 2026-08-07 | $732.92K 10-K/A · filed 2026-03-27 |
| 2025-09-30 | $372.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $500.09K derived: sum of 2 quarters · filed 2026-08-07 | $567.80K 10-Q · filed 2025-11-07 | $1.07M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $127.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $195.34K 10-Q · filed 2026-08-07 | $702.49K derived: sum of 3 quarters · filed 2026-08-07 | $974.04K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $67.71K 10-Q · filed 2026-05-07 | $574.86K derived: sum of 2 quarters · filed 2026-05-07 | $846.41K derived: sum of 3 quarters · filed 2026-05-07 | $943.48K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $507.15K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $778.69K derived: sum of 2 quarters · filed 2026-03-27 | $875.77K derived: sum of 3 quarters · filed 2026-03-27 | $1.18M 10-K/A · filed 2026-03-27 |
| 2024-09-30 | $271.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $368.62K derived: sum of 2 quarters · filed 2025-11-07 | $670.53K 10-Q · filed 2025-11-07 | $683.71K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $97.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $398.99K 10-Q · filed 2025-08-08 | $412.16K derived: sum of 3 quarters · filed 2025-08-08 | |
| 2024-03-31 | $301.91K 10-Q · filed 2025-05-08 | $315.09K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $13.18K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $52.09K 10-K · filed 2025-03-25 | ||
| 2023-09-30 | $38.91K 10-Q · filed 2024-11-12 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $0.00 derived: sum of 2 quarters · filed 2023-03-27 | $0.00 derived: sum of 3 quarters · filed 2023-03-27 | $802.00 10-K · filed 2023-03-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $802.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $802.00 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $802.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |